A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors.

Trial Profile

A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors.

Suspended
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2010

At a glance

  • Drugs Elesclomol (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Jun 2010 12-month survival results reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Synta media release.
    • 27 Feb 2009 Status changed from active, no longer recruiting to discontinued. The reasons for the decision to suspend this trial have been reported in a Synta Pharmaceuticals media release.
    • 12 Feb 2009 Dosing has commenced according to a Synta Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top